The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
Recruiting now · Phase 4
Conditions studied: Aging
In brief
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
Key facts
- Study ID
- NCT06128915
- Run by
- State University of New York at Buffalo
- People needed
- 60
- Starts
- 2024-01-08
- Expected to finish
- 2027-05-31
- Last updated by the study team
- 2026-04-03
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Both sexes
- Have not been vaccinated with any licensed or experimental pneumococcal vaccine
- Ages 21-40; and ≥65. Individuals >60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
- Free of acute infections within the last 2 weeks
- Did not take any anti-inflammatory medicine in the last week
- Did not ingest alcohol in the last 24 hours
- Ability and willingness to provide consent
You may not qualify if…
- Previous vaccination with any licensed or experimental pneumococcal vaccine
- Known hypersensitivity to vaccination and vaccine components
- Immune deficiency
- Use of immune-modulating or suppressive drugs
- Malignancies within the last 2 years
- Known hematological, rheumatic and inflammatory diseases
- Known chronic infections
- Poorly controlled chronic cardiovascular and metabolic conditions
- Pregnancy
- Dementia
Where it is running
- University at Buffalo — Buffalo, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.